Turn AI Risk Into Regulatory Readiness
Pharma quality teams are already facing regulatory warning letters citing AI overreliance, inspection findings built on fabricated AI-generated content, and shadow AI use spreading through GxP-adjacent work with 77% of staff turning to ungoverned tools — all while EU GMP Annex 22 and the EU AI Act’s high-risk provisions close in fast.
The GxP Quality x AI Innovation Summit brings together senior QA, regulatory, and compliance leaders across GCP, GMP, and GDP to convert AI ambition into validated, inspection-ready practice — grounded in real enforcement cases, not hype.